Technical Data
Plasminogen Activator Inhibitor Type 1 (PAI 1)
Plasminogen Activator Inhibitor 1 (PAI-1) is a glycoprotein found in plasma that is implicated in the processes of angoigenisis, hemostasis, tumor metastasis, fibrionlysis, ovulation, embryonic development and inflammation. The elevation of PAI-1 has shown to correlate with the prognosis of many cancers including breast cancer. PAI-1 is activated by the glycoprotein vitronectin. Vitronectin binds to PAI-1 and modulates fibrinolysis and cell migration. This binding has proven to be an important inhibitor of the activated form of protein C (APC).

Suitable for use in ELISA and Immunohistochemistry. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry: 10ug/ml
Optimal dilutions to be determined by the researcher.

NSO cells with spleen cells from BALB/c mouse

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
MabIgG15F119Affinity Purified
500ug-20CBlue IceHumanMouse
~1mg/ml (after reconstitution)
PAI from human melanoma cell line MJZJ.
Purified by Protein G affinity chromatography.
Supplied as a lyophilized powder from PBS, pH 7.4, 0.02% sodium azide. Reconstitute with 500ul sterile ddH2O.
Recognizes human active PAI-1, latent PAI-1, inactive PAI-1 and t-PA-PAI-1 complexes. Does not recognize PAI-2 or PAI-3.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Wagner, O.F., Vetterlein, M. and Binder, B.R., Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J. Biol. Chem. 261: 14,474-14,481 (1986).